Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma

Surgery (United States)

Volumn 154, Issue 6, 2013, Pages 1255-1262

  Kunstman, John W ^a   Korah, Reju ^a   Healy, James M ^a   Prasad, Manju ^a   Carling, Tobias ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RESTRICTION ENDONUCLEASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; THYROID CARCINOMA; THYROID GLAND; TUMOR INVASION; TUMOR VOLUME;

ADULT; AGED; CARCINOMA; CARCINOMA, PAPILLARY; CASE-CONTROL STUDIES; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84888007553     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2013.06.025     Document Type: Article

References (25)

1. B.A. Kilfoy, T. Zheng, T.R. Holford, X. Han, M.H. Ward, and A. Sjodin International patterns and trends in thyroid cancer incidence, 1973-2002 Cancer Causes Control 20 2009 525 531
2. M. Xing BRAF mutation in thyroid cancer Endocr Relat Cancer 12 2005 245 262
3. K.L. Kojic, S.L. Kojic, and S.M. Wiseman Differentiated thyroid cancers: a comprehensive review of novel targeted therapies Expert Rev Anticancer Ther 12 2012 345 357
4. J.D. Prescott, P.M. Sadow, R.A. Hodin, L.P. Le, R.D. Gaz, and G.W. Randolph BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence Surgery 152 2012 984 990
5. M. Xing Molecular pathogenesis and mechanisms of thyroid cancer Nat Rev Cancer 13 2013 184 199
6. O.P. Eze, L.F. Starker, and T. Carling The role of epigenetic alterations in papillary thyroid carcinogenesis J Thyroid Res 2011 2011 895470
7. P. Hou, M. Ji, and M. Xing Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors Cancer 113 2008 2440 2447
8. H. Zuo, M. Gandhi, M.M. Edreira, D. Hochbaum, V.L. Nimgaonkar, and P. Zhang Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors Cancer Res 70 2010 1389 1397
9. M. Gordon, and S. Baksh RASSF1A: Not a prototypical Ras effector Small GTPases 2 2011 148 157
10. N. Nakamura, J.A. Carney, L. Jin, S. Kajita, J. Pallares, and H. Zhang RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors Lab Invest 85 2005 1065 1075
11. U. Schagdarsurengin, O. Gimm, H. Dralle, C. Hoang-Vu, and R. Dammann CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma Thyroid 16 2006 633 642
12. U. Schagdarsurengin, O. Gimm, C. Hoang-Vu, H. Dralle, G.P. Pfeifer, and R. Dammann Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma Cancer Res 62 2002 3698 3701
13. M. Xing, Y. Cohen, E. Mambo, G. Tallini, R. Udelsman, and P.W. Ladenson Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis Cancer Res 64 2004 1664 1668
14. S.M. Lee, W.K. Lee, D.S. Kim, and J.Y. Park Quantitative promoter hypermethylation analysis of RASSF1A in lung cancer: comparison with methylation-specific PCR technique and clinical significance Mol Med Rep 5 2012 239 244
15. A.T. Martins, P. Monteiro, J. Ramalho-Carvalho, V.L. Costa, M. Dinis-Ribeiro, and C. Leal High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions Breast Cancer Res Treat 129 2011 1 9
16. M. Xing, V. Vasko, G. Tallini, A. Larin, G. Wu, and R. Udelsman BRAF T1796A transversion mutation in various thyroid neoplasms J Clin Endocrinol Metab 89 2004 1365 1368
17. A. Santoro, G. Pannone, M.A. Carosi, A. Francesconi, E. Pescarmona, and G.M. Russo BRAF mutation and RASSF1A expression in thyroid carcinoma of southern Italy J Cell Biochem 114 2013 1174 1182
18. R. Dammann, C. Li, J.H. Yoon, P.L. Chin, S. Bates, and G.P. Pfeifer Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 Nat Genet 25 2000 315 319
19. M.O. Hoque, E. Rosenbaum, W.H. Westra, M. Xing, P. Ladenson, and M.A. Zeiger Quantitative assessment of promoter methylation profiles in thyroid neoplasms J Clin Endocrinol Metab 90 2005 4011 4018
20. S.J. Lee, M.H. Lee, D.W. Kim, S. Lee, S. Huang, and M.J. Ryu Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma PloS One 6 2011 e16180
21. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin, and S.B. Baylin Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci U S A 93 1996 9821 9826
22. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, and S.J. Mandel Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 2009 1167 1214
23. H.J. Kim, S.Y. Sohn, H.W. Jang, S.W. Kim, and J.H. Chung Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma World J Surg 37 2013 376 384
24. Q. Zhao, J. Ming, C. Liu, L. Shi, X. Xu, and X. Nie Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma Ann Surg Oncol 20 2013 746 752
25. G. Malpeli, E. Amato, M. Dandrea, C. Fumagalli, V. Debattisti, and L. Boninsegna Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1C in pancreatic endocrine tumors BMC Cancer 11 2011 351